“Extreme Interviewing” – MSL Interview Tips and Insights from Medical Affairs Leaders

Extreme Interviewing, Medical Science Liaison, Emotional Intelligence, Hiring Process, Interview Tips

What is “Extreme Interviewing”? Is there such a thing? Does this term even exist in the dictionary? The short, and maybe obvious, answer is “No.” So perhaps I am guilty of coining a new term for the purpose of this article, but it is a concept that is very relevant and worth…

Jul 9^th • 1 min read

MSL People Skills: Top 10 Tips for Better Engagement

Medical Science Liaison, relationship building, business etiquette, social awareness, emotional intelligence, professional interactions, Dale Carnegie, How to Win Friends and Influence People, professional brand, engagement tips, digital communication

The cornerstone of the Medical Science Liaison role is RELATIONSHIP BUILDING. In a nutshell, better engagement equates to better relationships. The purpose of this article is to address the importance of proper business etiquette and the impact of social awareness and emotional intelligence as it re…

Apr 20^th • 8 mins read

Biosimilars in oncology: key role of nurses in patient education

biologics, biosimilars, cancer care, nurse

Biosimilars can reduce costs and improve access to cancer therapies, but unfamiliarity may hinder their adoption. Nurses, as trusted healthcare providers, are crucial in educating patients about biosimilars. Biosimilars are highly regulated and offer benefits comparable to existing biologic…

Jun 15^th • 10 mins read

Timing of first-in-child trials of FDA-approved oncology drugs

pediatric cancer; phase 1 trials; drug development; targeted therapy; disparity

  Aim: To define the lag time between initial human studies and first-in-child clinical trials of oncology agents. Methods: Systematic analysis of time from first-in-human trials to first-in-child trials for agents approved by the FDA from 1997 to 2017. Dat…

Mar 18^th • 10 mins read

The rise of oncology biosimilars: from process to promise

biologic, biosimilar, breast cancer, SB3, trastuzumab

Biosimilars are biologic products that are highly similar to the approved originator molecule, with no clinically meaningful differences. They are expected to play a key role in cancer treatment by reducing costs and improving access. Regulatory bodies use robust mechanisms for approval, involvi…

Aug 23^rd • 18 mins read